Roivant Sciences Ltd (ROIV)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 03/31
| 12-2024 | 09-2024 | 06-2024 | 03-2024 | 12-2023 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -104,359 | -222,434 | 57,490 | 4,231,206 | 4,413,702 |
| Depreciation Amortization | 12,646 | 9,725 | 4,883 | 22,036 | 16,811 |
| Accounts payable and accrued liabilities | -18,003 | -18,057 | -25,267 | 22,684 | 1,797 |
| Other Working Capital | -111,530 | -58,425 | -68,735 | 19,035 | 3,080 |
| Other Operating Activity | -445,640 | -170,444 | -161,200 | -5,060,229 | -5,092,201 |
| Operating Cash Flow | $-666,886 | $-459,635 | $-192,829 | $-765,268 | $-656,811 |
| Cash Flows From Investing Activities | |||||
| Change In Deposits | -3,101,521 | -3,402,985 | N/A | N/A | N/A |
| PPE Investments | -3,788 | -1,961 | -965 | -1,382 | -1,033 |
| Net Acquisitions | 264,824 | 110,387 | N/A | 5,196,413 | 5,197,217 |
| Other Investing Activity | 0 | 0 | 0 | 8,592 | 511 |
| Investing Cash Flow | $-2,840,485 | $-3,294,559 | $-965 | $5,203,623 | $5,196,695 |
| Cash Flows From Financing Activities | |||||
| Debt Repayment | -51,979 | -3,000 | -1,500 | -29,158 | -21,815 |
| Common Stock Issued | 37,654 | 9,539 | 2,271 | 493,825 | 490,170 |
| Common Stock Repurchased | -997,787 | -754,439 | -648,385 | -41 | -41 |
| Dividend Paid | N/A | N/A | N/A | -6,000 | -6,000 |
| Other Financing Activity | -30,529 | -21,790 | -13,002 | -39,262 | -10,326 |
| Financing Cash Flow | $-1,042,641 | $-769,690 | $-660,616 | $419,364 | $451,988 |
| Exchange Rate Effect | 1,236 | 2,303 | -2,740 | 616 | 1,471 |
| Beginning Cash Position | 6,550,450 | 6,550,450 | 6,550,450 | 1,692,115 | 1,692,115 |
| End Cash Position | 2,001,674 | 2,028,869 | 5,693,300 | 6,550,450 | 6,685,458 |
| Net Cash Flow | $-4,548,776 | $-4,521,581 | $-857,150 | $4,858,335 | $4,993,343 |
| Free Cash Flow | |||||
| Operating Cash Flow | -666,886 | -459,635 | -192,829 | -765,268 | -656,811 |
| Capital Expenditure | -3,788 | -1,961 | -965 | -1,382 | -1,033 |
| Free Cash Flow | -670,674 | -461,596 | -193,794 | -766,650 | -657,844 |